Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
19,770,250
-
Total 13F shares
-
378,983
-
Share change
-
+378,936
-
Total reported value
-
$769,811
-
Price per share
-
$2.03
-
Number of holders
-
31
-
Value change
-
+$769,716
-
Number of buys
-
29
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q1 2025
As of 31 Mar 2025,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
378,983 shares.
The largest 10 holders included
Murchinson Ltd., UBS Group AG, GOLDMAN SACHS GROUP INC, BlackRock, Inc., GEODE CAPITAL MANAGEMENT, LLC, Beacon Pointe Advisors, LLC, VANGUARD GROUP INC, WELLS FARGO & COMPANY/MN, Virtu Financial LLC, and BARCLAYS PLC.
This page lists
31
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.